Vir Biotechnology (NASDAQ:VIR) EVP Sells $134,534.00 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 13,700 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $9.82, for a total transaction of $134,534.00. Following the completion of the transaction, the executive vice president directly owned 112,982 shares in the company, valued at $1,109,483.24. The trade was a 10.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, February 24th, Verneuil Vanina De sold 3,117 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.53, for a total transaction of $29,705.01.
• On Monday, February 23rd, Verneuil Vanina De sold 4,445 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.45, for a total transaction of $33,115.25.

Vir Biotechnology Stock Performance

VIR traded down $0.68 during trading on Thursday, reaching $9.32. The stock had a trading volume of 21,297,439 shares, compared to its average volume of 3,752,478. The business has a 50-day moving average of $6.88 and a 200-day moving average of $6.02. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $10.94. The stock has a market cap of $1.30 billion, a PE ratio of -2.95 and a beta of 1.69.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. The firm had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The company’s revenue for the quarter was up 417.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.76) EPS. Equities research analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Vir Biotechnology

Several hedge funds have recently made changes to their positions in VIR. Raymond James Financial Inc. bought a new position in shares of Vir Biotechnology during the second quarter valued at approximately $35,000. FNY Investment Advisers LLC bought a new stake in Vir Biotechnology in the third quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. increased its position in Vir Biotechnology by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after purchasing an additional 1,390 shares during the period. UMB Bank n.a. raised its holdings in Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after purchasing an additional 6,597 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after purchasing an additional 4,899 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas collaboration materially derisks VIR‑5500 and adds near‑term cash/validation — the global co‑development/co‑commercialization deal includes significant upfront/near‑term payments and up to large milestone upside, boosting the program’s commercial outlook. Astellas and Vir Biotechnology collaborate on VIR-5500
• Positive Sentiment: Updated Phase 1 data for VIR‑5500 show encouraging safety and activity (notable higher‑dose response rates), supporting the asset value that underpins the Astellas deal. VIR-5500 Phase 1 results
• Positive Sentiment: Quarterly beat and revenue surge: Q4 EPS topped estimates and revenue (~$64.1M) far exceeded consensus, helping justify higher analyst targets and fueling recent upside. Vir Q4 earnings highlights
• Positive Sentiment: Analyst support: Needham and other firms raised targets/ratings after the results and deal news, reinforcing bullish institutional views. Needham raises VIR price target
• Neutral Sentiment: Management will be highly visible to investors in March (TD Cowen, Leerink) — useful for clarification on milestones, commercialization plans and cash use. Investor conference participation
• Neutral Sentiment: Media and valuation pieces are amplifying interest and volume — increased coverage raises visibility but doesn’t change fundamentals alone. Valuation after collaboration & Phase 1 update
• Negative Sentiment: Public offering priced: Vir priced 17,647,058 shares at $8.50 (gross proceeds about $150M). Proceeds bolster the balance sheet but the issuance is dilutive and can pressure the stock near term. Public offering priced
• Negative Sentiment: Clustered insider selling: Multiple insiders (CEO, EVPs, CFO, CAO, a director) reported stock sales across Feb. 23–25 — increases visible supply and can weigh on sentiment despite company progress. Insider selling report
• Negative Sentiment: Ongoing losses: Despite revenue growth and partnership cash, Vir reported a sizable net loss and wide negative margins — long‑term upside depends on execution, milestones and commercial ramp. 2025 financial results

Analyst Ratings Changes

Several research firms have commented on VIR. Morgan Stanley lifted their price target on shares of Vir Biotechnology from $20.00 to $24.00 and gave the stock an “overweight” rating in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a report on Tuesday, December 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Leerink Partners restated an “outperform” rating and set a $20.00 price target on shares of Vir Biotechnology in a research report on Thursday. Finally, Needham & Company LLC lifted their price objective on Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vir Biotechnology presently has an average rating of “Moderate Buy” and an average target price of $19.89.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.